Top Markets
Coin of the day
Cell Source, Inc. Cell Source, Inc.

Cell Source, Inc.

CLCS
Rang in Aktien #28218
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based... Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Aktienkurs
$0.4
Zuletzt synchronisiert: 2026-10-02
Marktkapitalisierung
$27.18M
Veränderung (1 Tag)
-14.88%
Veränderung (1 Jahr)
8.11%
Land
US
Handel Cell Source, Inc. (CLCS)

Kategorie

Dividendenrendite-Verlauf für Cell Source, Inc. (CLCS)
Dividendenrendite (TTM) von Cell Source, Inc. (Aktienkürzel: CLCS) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Cell Source, Inc. (CLCS) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
US
2.27%
AU
0.00%
NL
0.00%
CH